Introducing IRO®.
The new standard in CGT manufacturing technology.
IRO® delivers superior biological performance alongside the benefits of automation so you can maximize your clinical and commercial impact.
Ori is empowering scientists with flexible tools that streamline development and help to enable widespread patient access to life-saving cell and gene therapies.
Historically, scientists have had to compromise biological performance for automation. With IRO®, there is no trade-off. Offering both flexibility and scalability, IRO® supports accelerated development, minimizes batch failures, increases throughput, and reduces costs.
Automate Better Biology
Achieve superior biological results via a novel bioreactor and automated sterile connection technology, Ori Connect™.
Accelerate Product Development
Reach value inflection points more quickly with one platform, from R&D to GMP.
Scale Your Impact
Fit-for-purpose, flexible, digital manufacturing platform to deliver CGT products at scale, derisking the path to commercial viability.
"I expected automation, I expected more process insights, but I never expected better biological performance right out of the gate."
Jason Bock, Co-Founder and CEO
CTMC – a joint venture between Resilience + MD Anderson Cancer Center
The latest learnings, opinions, and events
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
March 18, 2025 – Preferred Partner Network (PPN) members will …
Read more
Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and Commercial CGT Manufacturers
January 7, 2025 – Six months after its unveiling, the …
Read more
Let’s enable widespread patient access, together.
Oribiotech Ltd 2025 © All rights reserved.
Oribiotech Ltd is registered in England and Wales. "Ori”, “Ori Biotech”, "Iro" and the O icon are registered trademarks of Oribiotech Ltd.
Company registration 09757696.
